In August 2022, the Spanish Ministry of Health published its “Public Health Strategy 2022” with the aim of improving well-being and health in the country. Among the listed priorities, a focus on the prevention of disease by tackling behavioural and environmental risk factors, that notably cause lung cancer in the Spanish population, has been included.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders in promoting lung health across Spain by developing national strategies.

Societal economic cost by disease:

- Asthma: €2.6 billion
- COPD: €13.5 billion
- Interstitial Lung Disease: €1.5 billion
- Lower Respiratory Tract Infections: €4.2 billion
- Mesothelioma: €257.9 million
- Lung Cancer: €13.9 billion
- Tuberculosis: €199.9 million
- Mesothelioma: €257.9 million
- Tuberculosis: €199.9 million

This initiative is made possible with the contributions of the partner organisations who all support the IRC’s goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Moderna, Amgen, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.

Data taken from IRC Lung Facts https://international-respiratory-coalition.org/lung-facts/diseases/